Buying pressure lifts Moderna higher in today trading

Traders Union
All News
Financial News
Moderna rises 3.65% today to $51.69

Highlights

The FDA has reversed course and agreed to review Moderna's mRNA-1010 seasonal flu vaccine with a Prescription Drug User Fee Act decision expected by August 5.
Telemark Asset Management LLC acquired 500,000 Moderna shares, while Aberdeen Group plc and Vanguard Group Inc. reduced their holdings, reflecting shifting institutional positioning.
MRNA trades at $51.69, well above the MA-20 ($44.24), MA-50 ($38.42), and MA-200 ($29.75), signaling bullish momentum with near-term resistance at $53.96.

Regulatory review and shifting holdings drive vaccine pipeline focus

The U.S. Food and Drug Administration has reversed its previous decision and agreed to review Moderna's seasonal flu vaccine candidate, mRNA-1010, with a Prescription Drug User Fee Act decision date set for August 5. Recent institutional activity includes Telemark Asset Management LLC acquiring 500,000 shares, while Aberdeen Group plc and Vanguard Group Inc. reported reductions in their holdings. These corporate actions and regulatory advances highlight continued focus on Moderna's vaccine pipeline.

Anton Kharitonov, expert at Traders Union, sees Moderna’s price stretched far above long-term averages. He views the bullish momentum as overextended, with multiple oscillators flashing overbought signals. Recent share reductions by institutional holders such as Vanguard raise concerns. Regulatory news on the vaccine pipeline is promising, but the sustainability of these gains is questionable. He warns, "Investors should be careful at these levels, as sharp reversals are possible once momentum fades."

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s strong uptrend reflects growing optimism in its mRNA pipeline. He emphasizes that FDA’s willingness to review mRNA-1010 showcases regulatory validation and opportunity for further growth. Positive institutional activity and robust technicals reinforce the bullish structure. Karapetjanc sees further upside likely should resistance at $53.96 break. He states, "The bullish structure remains intact, and new highs are within reach as market sentiment strengthens."

Parshwa Turakhiya, analyst, sees strong short-term momentum driving MRNA into overbought territory. He notes recent news is lifting sentiment, but cautions that oscillators signal a possible pause or retracement. The price could consolidate between $45.85 and $52.63 before a decisive move. He remarks, "Traders should watch for range-bound setups and be ready for volatility around intraday levels."

Overbought signals intensify as technical support and trend strengthen

Momentum signals for MRNA remain strong, with both MACD and ADX highlighting a bullish environment. Oscillators such as Stoch RSI and CCI indicate overbought conditions, while RSI is near 69, signaling stretched but persistent upside momentum. Bull Power is dominant, as shown by the pronounced BBP overbought reading, and the Awesome Oscillator confirms the current uptrend. Dynamic support stands at $45.93, with intraday resistance likely near $53.96 and additional resistance at round numbers above.

Previously it was reported that Moderna Inc. is trading above all key moving averages, with bullish momentum confirmed by strong MACD and ADX readings as momentum indicators highlight sustained buying pressure. However, multiple overbought signals and proximity to resistance near $50 suggest that while the uptrend persists, the risk of near-term pullbacks or consolidation is elevated.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.